Format

Send to

Choose Destination
Orphanet J Rare Dis. 2016 Nov 21;11(1):154.

An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry.

Author information

1
aHUS Alliance, Knutsford, Cheshire, UK. info@ahusallianceaction.org.
2
Department of Paediatric Nephrology, Great North Children's Hospital, Newcastle upon Tyne, UK.
3
Department of Pediatric Nephrology, Safepedrug Consortium, Ghent University Hospital, Ghent, Belgium.
4
Ghent University, Ghent, Belgium.
5
Alexion Pharma GmbH, Zurich, Switzerland.
6
Division of Nephrology, The Hospital for Sick Children, Toronto, Canada.
7
Paediatric Nephrology, University Hospital Vall d'Hebron, Barcelona, Spain.

Abstract

BACKGROUND:

Patients are becoming increasingly involved in research which can promote innovation through novel ideas, support patient-centred actions, and facilitate drug development. For rare diseases, registries that collect data from patients can increase knowledge of the disease's natural history, evaluate clinical therapies, monitor drug safety, and measure quality of care. The active participation of patients is expected to optimise rare-disease management and improve patient outcomes. However, few reports address the type and frequency of interactions involving patients, and what research input patient groups have. Here, we describe a collaboration between an international group of patient organisations advocating for patients with atypical haemolytic uraemic syndrome (aHUS), the aHUS Alliance, and an international aHUS patient registry (ClinicalTrials.gov NCT01522183).

RESULTS:

The aHUS Registry Scientific Advisory Board (SAB) invited the aHUS Alliance to submit research ideas important to patients with aHUS. This resulted in 24 research suggestions from patients and patient organisations being presented to the SAB. The proposals were classified under seven categories, the most popular of which were understanding factors that cause disease manifestations and learning more about the clinical and psychological/social impact of living with the disease. Subsequently, aHUS Alliance members voted for up to five research priorities. The top priority was: "What are the outcomes of a transplant without eculizumab and what non-kidney damage is likely in patients with aHUS?". This led directly to the initiation of an ongoing analysis of the data collected in the Registry on patients with kidney transplants.

CONCLUSION:

This collaboration resulted in several topics proposed by the aHUS Alliance being selected as priority activities for the aHUS Registry, with one new analysis already underway. A clear pathway was established for engagement between a patient advocacy group and an international research network. This should ensure the development of a long-term partnership which clearly benefits both groups.

KEYWORDS:

Patient advocacy; Patient engagement; Registry; aHUS

PMID:
27871301
PMCID:
PMC5117495
DOI:
10.1186/s13023-016-0537-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center